← The Wire
SNDXNasdaq
Syndax Pharmaceuticals Inc
Pharmaceutical Preparations · DE · CIK 1395937
Syndax Pharmaceuticals develops combination cancer therapies, including revumenib and axatilimab
red 8-K · 90d
$1.62B
Market cap
$21.78
Last close
+2.2%
1D
+12.7%
5D
4.7M
Volume
Price · last 39 sessions+9.1%
May 4L $16.96 · H $21.78Jun 29
227
Total filings
Jun 10, 2026
Last filing
12/31
Fiscal year end
SC 13GKYNAM CAPITAL MANAGEMENT, LPFeb 14, 2024SC 13GSCHEDULE 13GFeb 13, 2024SC 13GSYNDAX PHARMACEUTICALS INCOct 31, 2023SC 13GSEC SCHEDULE 13GJan 10, 2023SC 13GSC 13GFeb 14, 2022SC 13GSC 13GDec 23, 2021SC 13GSYNDAX PHARMACEUTICALS INC.May 10, 2021SC 13GSC 13GFeb 2, 2021SC 13GSC 13GNov 4, 2020SC 13GSC 13GMay 11, 2020SC 13GSC 13GOct 9, 2019SC 13GSYNDAX PHARMACEUTICALS, INC.Apr 8, 2019SC 13GSC 13GFeb 8, 2019SC 13GTHE SCHEDULE 13GNov 29, 2018SC 13GTHE SCHEDULE 13GNov 14, 2017SC 13GSC 13GFeb 9, 2017SC 13GSC 13GJan 30, 2017SC 13GSCHEDULE 13G FOR SYNDAX PHARMACEUTICALS, INC. BY DOMAIN PARTNERS VIII, L.P.Jan 9, 2017SC 13GSEC SCHEDULE 13GSep 12, 2016SC 13GSC 13GApr 11, 2016
Insider Activity
In the 90 days to Feb 9, 2026: 2 sold $628K.
| Date | Insider | Action | Shares | Price | Value |
|---|---|---|---|---|---|
| Feb 9, 2026 | Metzger Michael AChief Executive Officer | Sell | 17,159 | $21.03 | $361K |
| Feb 9, 2026 | Goldan Keith A.Chief Financial Officer | Sell | 3,410 | $21.03 | $72K |
| Feb 6, 2026 | Metzger Michael AChief Executive Officer | Sell | 7,412 | $20.62 | $153K |
| Feb 6, 2026 | Goldan Keith A.Chief Financial Officer | Sell | 2,082 | $20.62 | $43K |
Open-market buys & sells (Form 4, transaction codes P/S). Source: SEC structured insider data.
Similar companies
Comparable business profile · signals at a glance